The Outcomes of Emergency Pharmacist Participation during Acute Myocardial Infarction
Abstract
Background
Current guidelines recommend door-to-balloon times of 90
min or less for patients presenting to the emergency department (ED) with ST-segment elevation myocardial infarction (STEMI).
Objectives
To determine if a clinical pharmacist for the ED (EPh) is associated with decreased door/diagnosis-to-cardiac catheterization laboratory (CCL) time and decreased door-to-balloon time.
Methods
A retrospective observational cohort study of ED patients with STEMI requiring urgent cardiac catheterization was conducted. Blinded data collection included timing of ED and CCL arrival, diagnostic electrocardiogram (ECG), and balloon angioplasty. For cases diagnosed after ED arrival, diagnosis time was substituted for door time. Diagnosis was the time ST elevations were evident on serial ECG. EPh present and not-present groups were compared. During the study period there were two EPhs and presence was determined by their scheduled time in the ED. Univariate and multivariate analyses was used to detect differences.
Results
Multivariate analysis of 120 patients, controlled for CCL staff presence and arrival by pre-hospital services, determined that EPh presence is associated with a mean 13.1-min (95% confidence interval [CI] 6.5–21.9) and 11.5-min (95% CI 3.9–21.5) decrease in door/diagnosis-to-CCL and door-to-balloon times, respectively. Patients were more likely to achieve a door/diagnosis-to-CCL time
≤
30
min (odds ratio [OR] 3.1, 95% CI 1.3–7.8) and
≤
45
min (OR 2.9, 95% CI–1.0, 8.5) and a door-to-balloon time
≤
90
min (OR 1.9, 95% CI 0.7–5.5) more likely when the EPh was present.
Conclusions
EPh presence during STEMI presentation to the ED is independently associated with a decrease in door/diagnosis-to-CCL and door-to-balloon times.
Keywords: pharmacist, acute myocardial infarction, ST-segment myocardial infarction, STEMI, door-to-balloon time
To access this article, please choose from the options below
This work was supported by The American Society of Health-System Pharmacists Foundation, Pharmacy Resident Practice-Based Research Grant (Grant # 226). Dr. Shah is supported by the Paul B. Beeson Career Development Award (1K23AG028942-01). Dr. Fairbanks is supported by a Career Development Award from the National Institutes of Health (NIBIB 1K08EB009090).
PII: S0736-4679(10)00524-X
doi:10.1016/j.jemermed.2010.06.011
© 2010 Elsevier Inc. All rights reserved.
